Memantine Treatment of Compulsive Buying

NCT ID: NCT00830375

Last Updated: 2019-07-29

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 10 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2008-12-01
• Study Completion Date: 2010-08-01

Brief Summary

This is an 8-week, open-labe study of memantine in the treatment of compulsive buying.

Detailed Description

The goal of the proposed study is to evaluate the efficacy of memantine in the treatment of compulsive buying. Sixteen subjects meeting criteria for compulsive buying will receive 8 weeks of open-label memantine. The hypothesis to be tested is that memantine will be effective and well tolerated in patients with compulsive buying. The proposed study will provide needed data on the treatment of a disabling disorder that currently lacks a clearly effective treatment.

Conditions

Compulsive Buying

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Memantine

10-30mg, memantine

Group Type: EXPERIMENTAL

Memantine

Intervention Type: DRUG

10-30mg, by mouth, daily

Interventions

Memantine

10-30mg, by mouth, daily

Intervention Type: DRUG

Other Intervention Names

Namenda

Eligibility Criteria

Inclusion Criteria

1. men and women age 18-65

2. current CB using the clinician-administered Structured Clinical Interview for Compulsive buying (SCI-CB)

3. buying behavior within 2 weeks prior to enrollment

Exclusion Criteria

1. infrequent buying (i.e. less than one time per week) that does not meet proposed criteria for CB

2. unstable medical illness or clinically significant abnormalities on laboratory tests or physical examination at screen

3. history of seizures

4. myocardial infarction within 6 months

5. current pregnancy or lactation, or inadequate contraception in women of childbearing potential

6. a need for medication other than memantine with possible psychotropic effects or unfavorable interactions;

7. clinically significant suicidality;

8. current Axis I disorder determined by the SCID and SCID-compatible modules for impulse control disorders, except for nicotine dependence

9. lifetime history of bipolar disorder type I or II, dementia, schizophrenia, or any psychotic disorder determined by SCID

10. current or recent (past 3 months) DSM-IV substance abuse or dependence;

11. positive urine drug screen at screening

12. initiation of psychotherapy or behavior therapy within 3 months prior to study baseline

13. previous treatment with memantine

14. treatment with investigational medication or depot neuroleptics within 3 months, with fluoxetine within 6 weeks, or with other psychotropics within 2 weeks prior to study baseline

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

University of Minnesota

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Jon Grant, MD

Role: PRINCIPAL_INVESTIGATOR

University of Minnesota

Locations

Ambulatory Research Center

Minneapolis, Minnesota, United States

University of Minnesota

Minneapolis, Minnesota, United States

Countries

United States

Related Links

http://www.impulsecontroldisorders.org

Impulse Control Disorders Clinic - University of Minnesota

Other Identifiers

0806M37821

Identifier Type: -

Identifier Source: org_study_id